The pharmacogenetics of coumarin therapy

Deepak Voora, Howard L. McLeod, Charles Eby, Brian F. Gage

Research output: Contribution to journalReview articlepeer-review

88 Scopus citations


Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

Original languageEnglish
Pages (from-to)503-513
Number of pages11
Issue number5
StatePublished - Jul 2005


  • Acenocoumarol
  • CYP enzyme system
  • Genetic
  • Pharmacogenetics
  • Phenprocoumon
  • Polymorphism
  • Warfarin


Dive into the research topics of 'The pharmacogenetics of coumarin therapy'. Together they form a unique fingerprint.

Cite this